The main role of the CAT is to evaluate applications for ATMPs submitted to EMA and draft an opinion, before the Committee for Medicinal Products for Human Use (CHMP) adopts a final opinion on the marketing authorisation of the medicine. CAT is also responsible for classification and certification of ATMPs. ATMPs are medicines for human use that are based on genes or cells. They offer ground-breaking new opportunities for the treatment of disease and injury. The CAT’s remit includes developing guidance documents, simplifying procedures, training assessors and organising scientific workshops.